3CL protease inhibitor RAY1216 tablets was approved by the Ethics Committee of the First Hospital of Jilin University

Beijing News On May 22, Zhongsheng Pharmaceutical issued an announcement that the Phase I clinical trial plan of Zhongsheng Ruichuang oral anti-new coronavirus 3CL protease inhibitor RAY1216 tablets was approved by the Ethics Committee of the First Hospital of Jilin University, and the first clinical trial plan was completed. subjects were enrolled.

Zhongsheng Pharmaceutical stated that the Phase I clinical trial of RAY1216 tablets is a randomized, double-blind, placebo-controlled, single/multiple administration dose escalation study, which mainly evaluates the effects of RAY1216 tablets on single and multiple administrations in healthy subjects. The safety, tolerability, pharmacokinetic characteristics and the effect of food on pharmacokinetics provide the basis for the determination of the dosage regimen of the follow-up phase II/III clinical trials of RAY1216 tablets.

RAY1216 is a potent and broad-spectrum anti-new coronavirus 3CL protease inhibitor developed by Zhongsheng Ruichuang with global independent intellectual property rights. Cut, and then block virus replication, to achieve the effect of anti-new coronavirus.